Research programme: anticancer therapeutics - PolyProx therapeutics
Alternative Names: Polyproxin™ molecules - PolyProxLatest Information Update: 28 May 2023
At a glance
- Originator University of Cambridge
- Developer PolyProx Therapeutics
- Class Antineoplastics; Peptides; Proteins
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer